Prelude Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Prelude Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,753	Closed	-$324K	–	2088
2018 Q3	$324K	Sell	16,753 -30,372	-64%	-$323K	0.02%	650
2018 Q2	$344K	Buy	+47,125	New	+$238K	0.02%	636
2017 Q4	–	Sell	-14,700	Closed	-$71K	–	1634
2017 Q3	$71K	Buy	14,700 +14,400	+4,800%	+$74.8K	0.01%	1000
2017 Q2	$2K	Buy	+300	New	+$1.49K	﹤0.01%	1531
2017 Q1	–	Sell	-100	Closed	–	–	1727
2016 Q4	$0	Buy	+100	New	+$515	﹤0.01%	1737

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Prelude Capital Management's PRQR Position: Q4 2018 in Review

Prelude Capital Management sold out of ProQR Therapeutics (PRQR) in Q4 2018, closing a stake of 16,753 shares — an estimated $324K sold.

Prelude Capital Management first reported a position in PRQR in Q4 2016 and held it in 5 quarters. The position peaked at $344K in Q2 2018. 57 funds tracked by Wall St. Rank hold PRQR as of Q4 2018.

Prelude Capital Management reported no remaining ProQR Therapeutics position as of Q4 2018 after selling out during the quarter.
Prelude Capital Management sold 16,753 ProQR Therapeutics shares in Q4 2018, an estimated $324K.
Prelude Capital Management first reported a position in ProQR Therapeutics in Q4 2016 and held it in 5 quarters.
Prelude Capital Management's ProQR Therapeutics position peaked at $344K in Q2 2018.
57 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.